Apogee Therapeutics falls after eczema drug shows lower response rate than rival treatments

Apogee Therapeutics

07/07/2025 19:17

Updates

** Shares of drug developer Apogee Therapeutics APGE.O fall 17.9% to $38.97

 ** On a scoring system called IGA0/1, which assesses the severity of the disease, company's experimental drug showed a 34.9% response rate

 ** This compared to 38% seen with Eli Lilly's LLY.N Ebglyss and 37% from Sanofi SASY.PA and Regeneron Pharmaceuticals' REGN.O Dupixent

 ** APGE is studying its drug APG777 to treat patients with moderate-to-severe atopic dermatitis, a chronic disease that causes inflammation, redness and irritation of skin

** "The stock weakness post-data is curious and possibly explained by slightly discordant but still statistically significant IGA results that look in line with Dupixent/Ebglyss" - BTIG

** Company says APG777 showed a high response rate with a 71% reduction in eczema severity, compared with placebo of 33.8%, at week 16 in Part A of the mid-stage study

 ** Expects to share the 280-patient study data from Part B in mid-2026

** Including session moves, stock down 13.1% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))